Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

Experimental hematology & oncology·2026
Same author

Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal study.

European journal of internal medicine·2026
Same author

Inborn errors of immunity: a structured model for paediatric-to-adult transition of care.

Frontiers in immunology·2026
Same author

Navigating primary and secondary immunodeficiency intersections: how to find IEI hidden within SID.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2026
Same author

Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.

Lupus science & medicine·2026
Same author

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis.

Annals of hematology·2026
Same journal

Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.

Clinical and experimental medicine·2026
Same journal

Clonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparison.

Clinical and experimental medicine·2026
Same journal

Silibinin promotes hepatocyte proliferation through PINK1/Parkin-mediated mitophagy to alleviate acetaminophen-induced liver injury.

Clinical and experimental medicine·2026
Same journal

Serum GRP78 as a potential biomarker for early liver injury and active fibrogenesis in alcohol-associated liver disease.

Clinical and experimental medicine·2026
Same journal

Beyond polarization: a receptor-centered framework for macrophage function and therapy in skin diseases.

Clinical and experimental medicine·2026
Same journal

UBA2: the gatekeeper of the sumoylation pathway and its multifaceted roles in human diseases and therapeutic prospects.

Clinical and experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.

Roberto Ria1, Teresa Cirulli, Teresa Giannini

  • 1Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, University of Bari Medical School, Policlinico, Piazza Giulio Cesare 11, Bari, Italy. ria@dimo.uniba.it

Clinical and Experimental Medicine
|September 16, 2008
PubMed
Summary
This summary is machine-generated.

Serum levels of fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), and platelet-derived growth factor-beta (PDGF-beta) decrease after radiotherapy in non-Hodgkin lymphomas (NHLs). This decline may predict treatment response and recurrence.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Experiment Videos

Last Updated: Jul 1, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Area of Science:

  • Oncology
  • Radiotherapy Research
  • Biomarker Discovery

Background:

  • Angiogenic cytokines play a role in cancer progression.
  • Radiotherapy can influence serum levels of these cytokines.
  • Understanding these changes is crucial for treatment optimization.

Purpose of the Study:

  • To investigate the changes in serum levels of fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and platelet-derived growth factor-beta (PDGF-beta) after radiotherapy in non-Hodgkin lymphomas (NHLs).
  • To determine if these changes correlate with patient age, tumor histotype, stage, and radiation dose.

Main Methods:

  • Serum samples were collected before and after radiotherapy.
  • Enzyme-linked immunosorbent assay (ELISA) was used to measure cytokine levels.
  • Statistical analysis correlated cytokine levels with clinical and dosimetric parameters.

Main Results:

  • FGF-2, VEGF, and PDGF-beta levels significantly decreased post-radiotherapy, correlating with radiation dose and treatment response.
  • HGF levels did not show a significant decrease.
  • VEGF and PDGF-beta decreased in parallel; no correlation was found with age, histotype, or stage.

Conclusions:

  • Radiotherapy leads to a decline in serum FGF-2, VEGF, and PDGF-beta in NHL patients.
  • These declining cytokine levels may serve as predictive markers for treatment efficacy and disease recurrence.